Floatz logo

Bemotuzumab

Triple-Negative Breast Cancer (TNBC)

Zhejiang Provincial People's HospitalN/AActive
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
81/ 100

Competitive context

447 Active assets in the Triple-Negative Breast Cancer (TNBC) cohort.

Asset / SponsorPhaseRating
Capivasertib
AstraZeneca
Phase 3BB
Cyclophosphamide
M.D. Anderson Cancer Center
Phase 4BB
Carboplatin
M.D. Anderson Cancer Center
Phase 4BB
Veliparib
National Cancer Institute (NCI)
Phase 3BB
Atezolizumab
European Institute of Oncology
Phase 3BB

View all 50 →

Same molecule, other indications

Bemotuzumab is also rated in:

SCLC, Extensive StageDormant
CCC
Indicative ·
53 / 100
View asset →
small cell lung carcinomaDormant
CCC
Indicative ·
53 / 100
View asset →
cancerDormant
D
Indicative ·
30 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →